Medytox said on the 19th that it received product approval for the fat-dissolving injectable "Newvizu" from the Ministry of Food and Drug Safety. Newvizu is effective in improving submental fat.
Newvizu is the first chemically synthesized drug developed by Medytox, with cholic acid as the main ingredient. Its acidity (pH) is similar to that of the human body. Injectables on the market show adverse reactions and pain, but the company said Newvizu has reduced such side effects.
Medytox began a phase 1 clinical trial of Newvizu in 2018. A Medytox official said, "Starting with the domestic market, we will enter the global market."
※ This article has been translated by AI. Share your feedback here.